Arie Belldegrun
Director at UroGen Pharma; Director at Allogene Therapeutics; Director at Ginkgo Bioworks Holdings. Based in South San Francisco, California.
- Rank
- 5599th of 14,644
- Companies held
- 3
- Largest holding
- URGN, 71.6% of total
- Latest SEC filing
- Feb 2, 2026
- Listed but not counted
- $2.3M
What the $18.1M is made of
Holdings counted
All filings on SEC.gov| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| UroGen Pharma URGN Ordinary Shares | Directly | 408,693 | $31.73 | $13.0M | 71.6% | Form 4, Sep 14, 2022 |
| Allogene Therapeutics ALLO Common Stock | Through Bellco Legacy Trust | 4,710,120 | $0.67 | $3.1M | 17.4% | Form 4, Feb 2, 2026 |
| Allogene Therapeutics ALLO Common Stock | Directly | 2,236,816 | $0.67 | $1.5M | 8.2% | Form 4, Feb 2, 2026 |
| Allogene Therapeutics ALLO Common Stock | Through Bellco Legacy LLC | 539,867 | $0.67 | $360K | 2.0% | Form 4, Feb 2, 2026 |
| Ginkgo Bioworks Holdings DNA Class A Common Stock | Through Bellco Legacy LLC | 12,500 split-adjusted | $8.20 | $102K | 0.6% | Form 4, Jun 12, 2024 |
| Ginkgo Bioworks Holdings DNA Class A Common Stock | Directly | 4,873 split-adjusted | $8.20 | $40K | 0.2% | Form 4, Jun 12, 2024 |
Share counts are the amounts Arie Belldegrun reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.
Reported but not counted
These shares appear on Arie Belldegrun's filings but are held for charities, by investment funds the insider manages, or could not be valued reliably. Insiders usually disclaim ownership of fund holdings beyond their personal stake.
| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Allogene Therapeutics ALLO Common Stock | Through Vida Ventures LLC Held by an investment fund or partnership | 1,798,163 | $0.67 | $1.2M | — | Form 4, Feb 2, 2026 |
| Allogene Therapeutics ALLO Common Stock | Through Vida Ventures III, L.P. Held by an investment fund or partnership | 1,724,137 | $0.67 | $1.1M | — | Form 4, Feb 2, 2026 |
Nearby on the list
Full list| Rank | Name | Stock holdings |
|---|---|---|
| 5596 | Alex Bellos PRESIDENT WEST ELM BRAND, Williams-Sonoma. San Francisco, CA | $18.1M |
| 5597 | Annmarie Gayle Chairman, CEO, Coda Octopus Group. Orlando, FL | $18.1M |
| 5598 | Thomas C. Hutton vice president, Chemed. New York, NY | $18.1M |
| 5599 | Arie Belldegrun Director, UroGen Pharma. South San Francisco, CA | $18.1M |
| 5600 | Mark Stephen LaVigne PRESIDENT AND CEO, Energizer Holdings. St. Louis, MO | $18.1M |
| 5601 | Roland O. Burns President & CFO, Comstock Resources. Frisco, TX | $18.1M |
| 5602 | Brian E. Shore Board Chairman & CEO, Park Aerospace. Westbury, NY | $18.1M |
Other UroGen Pharma insiders
All URGN insiders- Elizabeth A. Barrett$10.4MChief Executive Officer. #8561 overall
- Fred E. Cohen$2.2MDirector. #6368 overall
Questions
How much stock does Arie Belldegrun own?
Arie Belldegrun holds $18,103,237 in listed stock based on SEC filings and current prices, mostly UroGen Pharma (URGN). That ranks 5599th on the Stock Rich List.
Is this Arie Belldegrun's net worth?
No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.